Compare BioNano Genomics Inc (BNGO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PulteGroup, Inc. — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while PulteGroup, Inc. trades at $123.99 (market cap $23.73B). The key difference: PulteGroup, Inc. is far larger — about 1797.7× BioNano Genomics Inc's market cap, and PulteGroup, Inc. pays a 0.83% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PHM | |
|---|---|---|
Market Cap | $13.20M | $23.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $142.56 |
52-Week Low | $1.09 | $108.00 |
Enterprise Value | $15.81M | $23.69B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
PulteGroup (PHM) trades at $123.75, down 0.8% on the day, with a bullish technical signal but mixed recent earnings. The stock shows strong profitability with a 12.14% net margin and attractive valuation at a P/E of 11.97. Recent news highlights new community developments and market sensitivity to mortgage rates. Cash flow trends improved in 2025 with net cash flow of $355 million.
Outlook remains cautiously optimistic with a consensus price target of $146, implying 18% upside. Risks include housing affordability pressures and recent earnings misses. Analyst sentiment is balanced with 45% buy ratings. The stock's valuation and dividend support a constructive view amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
